🇺🇸 FDA
Patent

US 11278592

Methods and compositions for TUSC2 immunotherapy

granted A61KA61K2039/505A61K38/1709

Quick answer

US patent 11278592 (Methods and compositions for TUSC2 immunotherapy) held by The Board of Regents of the University of Texas System expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K38/1709, A61K39/39541, A61K45/06